| 摘要 |
Compositions useful for improving effectiveness of alpha-2-adrenergic agonist components are disclosed. These compositions include carrier components, alpha-2-adrenergenic agonist components, solubility enhancing components which aid in solubilizing the alpha-2-adrenergic agonist components. An aqueous ophthalmic composition is disclosed which comprises up to about 0.15% (w/v) of a component selected from the group consisting of 5-bromo-6-(2-imidozolin-2-ylamino) quinoxaline, salts of 5-bromo-6-(2-imidozolin-2-ylamino) quinoxaline, esters of 5-bromo-6-(2-imidozolin-2-ylamino) quinoxaline, and mixtures thereof, the composition having a pH of about 7.0 or greater and the component being soluble in the composition at about 21°C, the composition may also comprise a solubility enhancing agent and an aqueous liquid component. |
